Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Doxorubicin treatment outcomes for non-Hodgkin's lymphomas (NHL) are mathematically modelled and computationally analyzed. The NHL model includes a tumor structure incorporating mature and immature vessels, vascular structural adaptation and NHL cell-cycle kinetics in addition to Doxorubicin pharmacokinetics (PK) and pharmacodynamics (PD). Simulations provide qualitative estimations of the effect of Doxorubicin on high-grade (HG), intermediate-grade (IG) and low-grade (LG) NHL. Simulation results imply that if the interval between successive drug applications is prolonged beyond a certain point, treatment will be inefficient due to effects caused by heterogeneous blood flow in the system.

Original publication

DOI

10.1016/j.bulm.2004.06.007

Type

Journal article

Journal

Bull Math Biol

Publication Date

01/2005

Volume

67

Pages

79 - 99

Keywords

Cell Cycle, Cell Proliferation, Cell Survival, Computer Simulation, Doxorubicin, Humans, Kinetics, Lymphoma, Non-Hodgkin, Models, Theoretical, Regional Blood Flow, Time Factors, Treatment Outcome